Future Science Group
Browse
- No file added yet -

Pharmacokinetics and safety of CT-P17 (40 mg/0.4 ml) versus reference adalimumab: randomized study in healthy Japanese adults. Supplementary methods

Download (463.5 kB)
dataset
posted on 2023-02-07, 09:34 authored by Yoichiro Ogama, Sangmi Lee, JungBin Cha, Eunjin Choi, DaBee Jeon, Sunghyun Kim, Takanori Tanaka, Miwa Haranaka, YunJu Bae

  

Pharmacokinetics & safety of CT-P17 (40 mg/0.4 mL) vs reference adalimumab: randomised study in healthy Japanese adults: supplementary methods

History

Usage metrics

    Immunotherapy

    Categories

    Keywords

    safetyphase Ipharmacokineticsmonoclonal antibodiesJapanimmunogenicityCT-P17biosimilarbiologicsadalimumab

    Licence

    CC BY-NC-ND 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC